| アブストラクト | BACKGROUND: Some studies suggest that potential safety issues about PCSK9 inhibitors have not been sufficiently explored in clinical trials, including musculoskeletal adverse events (MAEs). OBJECTIVE: To examine the association between use of PCSK9 inhibitors with and without concurrent statins and risk of MAEs. Patients and Methods. FDA Adverse Event Reporting System (FAERS) dataset of PCSK9 inhibitors and statins from October 2015 to June 2021 was queried. The reporting odds ratio (ROR) with relevant 95% confidence interval (95% CI) was calculated as the index of disproportionality. Outcome of MAEs of different PCSK9 inhibitors regimens was also investigated. RESULTS: 3,185 cases of PCSK9 inhibitor-associated MAEs were recorded. PCSK9 inhibitor class alone demonstrated a strong link to MAEs (ROR 5.92; 95% CI 5.70-6.15), and evolocumab was associated with more reports of MAEs than alirocumab. Concomitant use with statins leaded to an increased occurrence of MAEs (ROR 32.15 (25.55-40.46)), and the risk differed among different statins. The PCSK9 inhibitors were safer than statins in terms of hospitalization rate and death rate (15.64% vs. 36.83%; 0.72% vs. 3.53%). CONCLUSIONS: This pharmacovigilance investigation suggests that PCSK9 inhibitors are associated with MAEs. The risk significantly increases when combined with statins. Increased laboratory and clinical monitoring are required to timely diagnose and manage MAEs. |
|---|
| ジャーナル名 | Cardiovascular therapeutics |
|---|
| Pubmed追加日 | 2022/2/11 |
|---|
| 投稿者 | Ding, Lingqing; Chen, Congqin; Yang, Yongkuan; Fang, Jie; Cao, Longxing; Liu, Yige |
|---|
| 組織名 | Department of Pharmacy, Xiamen Cardiovascular Hospital, Xiamen University, Xiamen;361024, China.;School of Electrical Engineering and Automation, Xiamen University of Technology,;Xiamen 361024, China.;Department of Pharmacy, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong;University, Shanghai 200003, China.;Department of Cardiovascular Medicine, Xiamen Cardiovascular Hospital, Xiamen;University, Xiamen 361024, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35140810/ |
|---|
